Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2023 - 2025)

Neuphoria Therapeutics (NEUP) has 3 years of Long-Term Deferred Tax data on file, last reported at $26.1 million in Q2 2025.

• Quarterly Long-Term Deferred Tax fell 5.78% year-over-year to $26.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $26.1 million (down 5.78% YoY) and the FY2025 annual result came in at $26.1 million, down 5.78% from the prior year.
• Long-Term Deferred Tax declined to $26.1 million in Q2 2025 per NEUP's latest filing, from $27.7 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $27.7 million in Q2 2024 and bottomed at $1.1 million in Q2 2023.
• The 3-year median for Long-Term Deferred Tax is $26.1 million (2025), against an average of $18.3 million.
• The widest annual swing landed in 2024, when Long-Term Deferred Tax jumped 2411.99%; it then dropped 5.78% in 2025.
• Tracing NEUP's Long-Term Deferred Tax over 3 years: stood at $1.1 million in 2023, then jumped by 2411.99% to $27.7 million in 2024, then declined by 5.78% to $26.1 million in 2025.
• Per Business Quant, the three latest NEUP Long-Term Deferred Tax figures stand at $26.1 million (Q2 2025), $27.7 million (Q2 2024), and $1.1 million (Q2 2023).

Peer Comparison